A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1445 | Th1079 | Serum Albumin | DAHKSEVAHRFKDLGEENFK Full view | 585 | IV | Metabolic/genetic | Albunex | Mallinckrodt; Tyco Healthcare | N.A. | Intravenous infusion | Serum substitutes | N.A. |
| 1446 | Th1079 | Serum Albumin | DAHKSEVAHRFKDLGEENFK Full view | 585 | IV | Metabolic/genetic | Optison | GE Healthcare | N.A. | Intravenous infusion | Serum substitutes | N.A. |
| 1453 | Th1083 | Coagulation Factor Ix | YNSGKLEEFVQGNLERECME Full view | 415 | Ia | Hematological/Metabolic/genetic | Alprolix | Biogen Idec Inc., and Genentech USA, Inc | Sterile, non-pyrogenic, preservative-free, white to off-white, lyophilized powder to cake for reconstitution with the provided diluent | Intravenous infusion | Coagulants and Thrombotic Agents | N.A. |
| 1455 | Th1085 | Agalsidase Beta | LDNGLARTPTMGWLHWERFM Full view | 398 | Ia | Metabolic | Fabrazyme | Genzyme Corp | Sterile, nonpyrogenic, white to off-white, lyophilized cake or powder for reconstitution with Sterile Water for Injection | N.A. | Enzyme Replacement Agents | N.A. |
| 1476 | Th1096 | Idursulfase | SETQANSTTDALNVLLIIVD Full view | 525 | Ia | Metabolic | Elaprase | SHIRE | Sterile, nonpyrogenic clear to slightly opalescent, colorless solution that must be diluted prior to administration in 0.9% Sodium Chloride Injection, USP | Intravenous infusion | Enzyme Replacement Agents | Dermatan sulfate,Heparan sulfate,Perilipin-3 |
| 1477 | Th1097 | Alglucosidase Alfa | AHPGRPRAVPTQCDVPPNSR Full view | 882 | Ic | Metabolic | LUMIZYME | Genzyme | Sterile, nonpyrogenic, white to off-white, lyophilized cake or powder for reconstitution with 10.3 Ml Sterile Water for Injection, USP | Intravenous infusion | Enzyme Replacement Agents | Cation-dependent mannose-6-phosphate receptor,Glycogen |
| 1478 | Th1098 | Exenatide | HGEGTFTSDLSKQMEEEAVR Full view | 39 | Ib | Hormonal/Metabolic | BYETTA | N.A. | N.A. | N.A. | Hypoglycemic Agents | Glucagon-like peptide 1 receptor |
| 1479 | Th1098 | Exenatide | HGEGTFTSDLSKQMEEEAVR Full view | 39 | Ib | Hormonal/Metabolic | BYDUREON | Amylin Pharmaceuticals | White to off-white powder that is available in a dosage strength of 2 mg exenatide per vial or per pen | N.A. | Hypoglycemic Agents | Glucagon-like peptide 1 receptor |
| 1482 | Th1100 | Pramlintide | KCNTATCATQRLANFLVHSS Full view | 37 | Ia | Hormonal/Metabolic | Symlin | Amylin Pharmaceuticals (now a wholly owned subsidiary of AstraZeneca) | Clear, isotonic, sterile solution | Subcutaneous injection | N.A. | Calcitonin receptor,Receptor activity-modifying protein 1,Receptor activity-modifying protein 2,Receptor activity-modifying protein 3 |
| 1494 | Th1101 | Galsulfase | SGAGASRPPHLVFLLADDLG Full view | 497 | Ia | Metabolic | Naglazyme | BioMarin | Sterile, nonpyrogenic, colorless to pale yellow, clear to slightly opalescent solution that must be diluted with 0.9% Sodium Chloride Injection, USP, prior to administration | Intravenous infusion | Enzyme Replacement Agents | Dermatan sulfate,Perilipin-3 |
| 1502 | Th1105 | Insulin Aspart | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | NovoLog | Novo Nordisk | Sterile, aqueous, clear, and colorless solution | Subcutaneous injection, Intravenous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
| 1503 | Th1105 | Insulin Aspart | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | NovoLog Mix 50/50 | Novo Nordisk | Uniform, white, sterile suspension that contains insulin aspart | Subcutaneous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
| 1504 | Th1105 | Insulin Aspart | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | NovoLog Mix 70/30 | Novo Nordisk | Uniform, white, sterile suspension that contains insulin aspart 100 Units/mL. | Subcutaneous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
| 1511 | Th1106 | Insulin Detemir | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | LEVEMIR | Novo Nordisk | Clear, colorless, aqueous, neutral sterile solution | Subcutaneous injection | Antidiabetic Agents | Insulin receptor |
| 1520 | Th1107 | Insulin Glulisine | A chain: GIVEQCCTSIC Full view | 51 | Ib | Hormonal/Metabolic | APIDRA | sanofi-aventis | Sterile, aqueous, clear, and colorless solution | N.A. | Antidiabetic Agents | Insulin receptor |
| 1634 | Th1140 | Insulin, Isophane Or Nph Insulin (Neutral Protamine Hagedorn) | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | Novolin N | Novo Nordisk | Novolin N InnoLet (nph, human insulin isophane suspension 3 ml disposable prefilled syringe) | Subcutaneous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
| 1648 | Th1148 | Aliskiren | N.A. Full view | 0 | IIa | Metabolic | Tekturna | Physicians Total Care, Inc. | Light-pink, biconvex round tablet | Oral route | Renin inhibitor | Renin |
| 1649 | Th1148 | Aliskiren | N.A. Full view | 0 | IIa | Metabolic | Tekturna | Novartis Pharmaceuticals Corporation | Light-pink, biconvex round tablet | Oral route | Renin inhibitor | Renin |
| 1650 | Th1148 | Aliskiren | N.A. Full view | 0 | IIa | Metabolic | Tekturna HCT | Novartis Pharmaceuticals Corporation | Biconvex, ovaloid film-coated tablets. | Oral route | Renin inhibitor | Renin |
| 1651 | Th1148 | Aliskiren | N.A. Full view | 0 | IIa | Metabolic | Tekamlo | Novartis Pharmaceuticals Corporation | Tablets (aliskiren/amlodipine): 150 mg/5 mg, 150 mg/10 mg, 300 mg/5 mg, 300 mg/10 mg | Oral route | Renin inhibitor | Renin |
| 1652 | Th1148 | Aliskiren | N.A. Full view | 0 | IIa | Metabolic | Amturnide | Novartis Pharmaceuticals Corporation | Tablets (aliskiren/ amlodipine/ HCTZ): 150/5/12.5, 300/5/12.5, 300/5/25, 300/10/12.5, 300/10/25 mg. | Oral route | Renin inhibitor | Renin |
| 1655 | Th1151 | Somatotropin Recombinant | FPTIPLSRLFDNAMLRAHRL Full view | 192 | Ib | Hormonal/Metabolic | NutropinAQ | Genentech Inc. | Sterile, white lyophilized powder intended for subcutaneous administration after reconstitution with Bacteriostatic Water | Subcutaneous administration | Hormone Replacement Agents | Growth hormone receptor, Prolactin receptor |
| 1656 | Th1151 | Somatotropin Recombinant | FPTIPLSRLFDNAMLRAHRL Full view | 192 | Ib | Hormonal/Metabolic | BioTropin | Bio-Technology General (Israel) Ltd. | Sterile, white, lyophilized powder | Subcutaneous administration | Hormone Replacement Agents | Growth hormone receptor, Prolactin receptor |
| 1657 | Th1151 | Somatotropin Recombinant | FPTIPLSRLFDNAMLRAHRL Full view | 192 | Ib | Hormonal/Metabolic | Protropin | Genentech Inc. | Sterile, white, lyophilized powder | Intramuscular or subcutaneous administration | Hormone Replacement Agents | Growth hormone receptor, Prolactin receptor |
| 1678 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis U.S. Llc | Injection, Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 9 |
| 1679 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis Canada Inc | Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 10 |
| 1680 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis Canada Inc | Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 11 |
| 1681 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis U.S. Llc | Injection, Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 14 |
| 1729 | Th1176 | Dulaglutide | HGEGTFTSDVSSYLEEQAAK Full view | 275 | Ib | Metabolic Disorders | Trulicity | Eli Lilly and Company | Solution, Injection | Subcutaneous | Hypoglycemic Agents; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Blood Glucose Lowering Drugs, Excl. Insulins | Glucagon-like peptide 1 receptor |
| 1730 | Th1176 | Dulaglutide | HGEGTFTSDVSSYLEEQAAK Full view | 275 | Ib | Metabolic Disorders | Trulicity | Eli Lilly Canada Inc | Solution | Subcutaneous | Hypoglycemic Agents; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Blood Glucose Lowering Drugs, Excl. Insulins | Glucagon-like peptide 1 receptor |
| 1736 | Th1177 | Elosulfase alfa | APQPPNILLLLMDDMGWGDL Full view | 496 | Ia | Metabolic Disorders | Vimizim | Biomarin International Limited | Solution | Intravenous | Enzymes; Alimentary Tract and Metabolism | N-acetylgalactosamine-6-sulfatase |
| 1741 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | NA | NA | Injection, Solution; Injection | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 9 |
| 1742 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Inc | Injection, Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 10 |
| 1743 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Canada Inc | Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 11 |
| 1744 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Inc | Injection, Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 12 |
| 1821 | Th1212 | Insulin Pork | A chain GIVEQCCTSICS Full view | 68 | Ia | Metabolic Disorders | Iletin II | Lilly | sterile suspension | Subcutaneous | Hypoglycemic Agents, Antidiabetic Agents | Insulin receptor, Insulin-like growth factor 1 receptor, Insulin-degrading enzyme, HLA class II histocompatibility antigen, DQ alpha 2 chain, HLA class II histocompatibility antigen, DQ beta 1 chain, Retinoblastoma-associated protein, Cathepsin D, Carboxypeptidase E, Neuroendocrine convertase 2, Neuroendocrine convertase 1, Protein NOV homolog, Low-density lipoprotein receptor-related protein 2, Insulin-like growth factor-binding protein 7, Synaptotagmin-like protein 4, Cytochrome P450 1A2 |
| 1822 | Th1213 | Insulin Degludec | Insulin degludec dif Full view | 0 | Ia | Metabolic Disorders | Tresiba | Novo Nordisk | sterile, aqueous, clear, and colorless Solution | Subcutaneous | NA | NA |
| 1823 | Th1214 | Insulin Beef | A chain: GIVEQCCASVC Full view | 71 | Ia | Metabolic Disorders | NA | NA | NA | NA | NA | NA |
| 1847 | Th1235 | Protein S human | ANSLLEETKQGNLERECIEE Full view | 635 | Ib | Metabolic Disorders | Protein S human | NA | Solid | NA | Anticoagulant plasma protein | NA |